Partners

University of Connecticut (UConn)

 

In July 2018, INHIBITOR entered into a one-year world-wide option agreement concerning itraconazole analogues, which are being developed by Dr. M. Kyle Hadden, Associate Professor of Medicinal Chemistry, Department of Pharmaceutical Sciences at UConn. These analogues have modifications to particular regions of the itraconazole scaffold. There are patents and patent applications which include compositions of matter claims covering the itraconazole analogues and method claims covering their use for the treatment of cancer.

Data from Dr. Hadden’s laboratory suggest that certain of these analogues maintain potent Hedgehog pathway inhibition while exhibiting improved pharmacokinetic parameters and reduced off-target side effects sometimes associated with itraconazole. INHIBITOR and UConn signed a one-year extension of the original world-wide option agreement in July 2019, which now includes additional new analogues and patent applications. The partnership with UConn will focus on pre-clinical animal testing of key analogues for treatment of human BCC tumors.

 

The University of Connecticut is one of the top 25 public research universities in the nation and is a research leader in the fields of advanced materials, additive manufacturing, biomedical devices, cybersecurity, energy, life sciences, sensors, and nanotechnology. As Connecticut’s flagship institution of higher education, UConn serves as an important resource for Connecticut economic development and is dedicated to building collaborations with industry and entrepreneurs with more than $3.6B in investment from the state of Connecticut and industry partners.